Qiagen (NYSE:QGEN) Updates FY 2026 Earnings Guidance

Qiagen (NYSE:QGEN) updated its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 2.430- for the period, compared to the consensus EPS estimate of 2.430. The company issued revenue guidance of $2.1 billion-$2.1 billion, compared to the consensus revenue estimate of $2.2 billion.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on QGEN. Jefferies Financial Group restated a “buy” rating and set a $48.00 target price on shares of Qiagen in a research note on Thursday. Weiss Ratings cut shares of Qiagen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, May 29th. Robert W. Baird set a $43.00 price objective on shares of Qiagen and gave the company an “outperform” rating in a research report on Wednesday, April 29th. JPMorgan Chase & Co. lowered their price objective on shares of Qiagen from $60.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 29th. Finally, Citigroup restated a “hold” rating on shares of Qiagen in a report on Monday, May 18th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $42.43.

Qiagen Price Performance

QGEN traded down $0.24 during trading hours on Thursday, hitting $41.71. The company’s stock had a trading volume of 4,028,165 shares, compared to its average volume of 2,442,216. The business’s 50-day moving average price is $39.21 and its 200-day moving average price is $41.73. The company has a current ratio of 3.21, a quick ratio of 2.57 and a debt-to-equity ratio of 0.49. The stock has a market cap of $8.59 billion, a price-to-earnings ratio of 21.78, a P/E/G ratio of 4.22 and a beta of 0.63. Qiagen has a 12 month low of $32.53 and a 12 month high of $57.81.

Qiagen (NYSE:QGEN) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. The business had revenue of $535.00 million for the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.The company’s quarterly revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.60 earnings per share. Qiagen has set its FY 2026 guidance at 2.430- EPS. Sell-side analysts expect that Qiagen will post 2.43 earnings per share for the current fiscal year.

Qiagen Increases Dividend

The company also recently disclosed an annual dividend, which was paid on Tuesday, July 14th. Shareholders of record on Tuesday, July 7th were paid a $0.35 dividend. The ex-dividend date of this dividend was Tuesday, July 7th. This is an increase from Qiagen’s previous annual dividend of $0.26. This represents a yield of 90.0%. Qiagen’s payout ratio is 18.32%.

Key Headlines Impacting Qiagen

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: Qiagen exceeded its second-quarter outlook, reporting $535 million in sales and adjusted diluted EPS of $0.62, compared with analyst estimates of $527.5 million and $0.60, respectively. Sales were roughly flat year over year but better than the company’s prior expectation for an approximately 2% constant-exchange-rate decline. QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
• Positive Sentiment: The company reaffirmed its full-year 2026 adjusted EPS outlook of approximately $2.43, in line with consensus, while maintaining solid profitability. Its growth pillars reportedly delivered 5% constant-exchange-rate growth, supporting the case for continued demand in key molecular diagnostics and life-sciences markets. Qiagen N.V. 2026 Q2 Results Earnings Call Presentation
• Neutral Sentiment: Qiagen’s second-quarter net margin was 19.16%, and revenue increased approximately 0.2% year over year. However, the earnings beat was modest, with EPS declining from $0.63 a year earlier to $0.62, indicating limited earnings growth so far.
• Negative Sentiment: Qiagen guided third-quarter 2026 EPS to approximately $0.62, below the $0.63 consensus estimate, and revenue to $538.3 million-$543.7 million, below analysts’ $552.7 million forecast. The revenue shortfall is likely the key reason for the stock’s weaker performance, despite the second-quarter beat. Full-year revenue guidance of roughly $2.1 billion also remains below the approximately $2.2 billion consensus expectation.

Institutional Investors Weigh In On Qiagen

Hedge funds and other institutional investors have recently modified their holdings of the business. O Shaughnessy Asset Management LLC bought a new stake in Qiagen during the 4th quarter valued at about $242,000. Quadrant Capital Group LLC grew its stake in Qiagen by 26.5% in the 3rd quarter. Quadrant Capital Group LLC now owns 5,273 shares of the company’s stock worth $236,000 after acquiring an additional 1,105 shares in the last quarter. Osaic Holdings Inc. increased its position in shares of Qiagen by 101.4% during the second quarter. Osaic Holdings Inc. now owns 3,875 shares of the company’s stock worth $185,000 after acquiring an additional 1,951 shares during the period. Pitcairn Co. purchased a new position in shares of Qiagen during the second quarter worth approximately $208,000. Finally, Evergreen Capital Management LLC bought a new stake in shares of Qiagen during the second quarter valued at approximately $246,000. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.